Scala Biodesign
Develops computational protein design technologies for therapeutic and industrial applications
$16MSeries A
Role not disclosedGV
Grove Ventures
Activity from announced rounds
Activity in this selectionMar 31, 2026 · AI · Mar 1, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $118M 3 disclosed · full round size, not this investor’s share